Submitted two additional U.S. government funding proposals during the quarter, bringing the total proposals to US$137 million
Accepted as a new member of U.S. Medical CBRN Defense Consortium, strengthening government and biodefense partnerships
HALIFAX, Nova Scotia, Aug. 14, 2025 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the first quarter of its fiscal year 2026, which ended on June 30, 2025. All figures are in Canadian dollars unless otherwise stated.
“Appili continues to strengthen our position within government and biodefense industries, highlighted by our recent participation in the U.S. Medical CBRN Defense Consortium (“MCDC”) Membership Meeting and the publication of new ATI-1701 data,” said Don Cilla, Pharm.D., M.B.A., President and CEO of Appili Therapeutics.
“In the first quarter of fiscal 2026, we focused on building commercial momentum for LIKMEZ®, advancing ATI-1701 through ongoing funded activities, and securing a partner for ATI-1801. With seven non-dilutive funding proposals submitted to U.S. government agencies—representing up to US$137 million— Appili is positioned to advance infectious disease and biodefense products.”
Update on U.S. Federal Government Funding Proposals
Appili has submitted a total of seven funding proposals to U.S. government agencies, representing a potential combined award value of up to US$137 million. This includes a recently submitted proposal to the Congressionally Directed Medical Research Program’s Peer Reviewed Medical Research Program (“PRMRP”) (described herein), two proposals submitted to the U.S. Medical CBRN Defense Consortium (“MCDC”), and two proposals submitted to the National Institute of Allergy and Infectious Diseases (“NIAID”). If awarded, the funding would support the development of these projects, advancing them through manufacturing, non-clinical development, and regulatory activities required for IND submissions, and Phase 1 clinical trials for the two proposals submitted to NIAID.
MCDC Membership
Appili was recently accepted as a member of the MCDC, further solidifying its role in U.S. preparedness and biodefense. With over US$7 billion in awarded project funding to date, the MCDC fosters public–private partnerships that accelerate the development of safe and effective medical countermeasures.
In July 2025, Dr. Gary Nabors, Chief Development Officer of Appili, participated in the MCDC Consortium event, joining government and industry leaders to align shared biodefense priorities. Through the consortium membership, Appili can actively engage with government stakeholders, collaborate with industry partners, and pursue new funding opportunities that align with the objectives of the DOD.
ATI-1701, Biodefense Vaccine Candidate with Funding Awarded from the U.S. Air Force Academy
ATI-1701, Appili’s live-attenuated vaccine candidate for the prevention of tularemia, continues to progress under a Cooperative Agreement with the U.S. Air Force Academy (“USAFA Cooperative Agreement”), with total program funding allotted of approximately US$11.6 million.
In July 2025, Appili’s …